MedGenome acquires Illumina’s NovaSeq X Plus; launches Genome Sequencing Test
MedGenome on Monday announced that it will now offer advanced genomics services using Illumina’s NovaSeq X Plus in South Asia. With this, the company anticipates bringing down the reagent cost of Human Whole Genome sequencing to USD $200 in the near future, it stated.
In conjunction with this acquisition, MedGenome is thrilled to launch KaryoSeq (or Karyotype Sequencing), an innovative Whole Genome Sequencing to diagnose prenatal and newborn conditions, it announced.
“The NovaSeq X Series is Illumina’s most powerful sequencing system. With the ability to generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers at shorter turnaround time, this latest sequencer is aimed at making genomics more sustainable and accessible to more people globally. MedGenome has had a long-standing partnership with Illumina over the last decade expanding its portfolio of sequencing equipment with the latest offerings and becoming leaders in adopting the most up to date sequencing technology. NovaSeq X Plus promises to accelerate a deeper understanding of genetic disorders and can perform a broad range of data-intensive applications, bringing more breakthroughs genetic disease diagnosis and treatment,” the company said in a statement.
MedGenome has launched several breakthrough tests in key disease areas in the last few years. According to the company’s press statement, the latest offering, KaryoSeq has significant advantages over traditional cytogenetic and molecular techniques.
The test is a faster and accurate solution which allows for the detection of small chromosomal abnormalities, such as microdeletions or microduplications, that may not be easily identified through microscopic examination alone, it
Read more on financialexpress.com
